Business context and reporting period
The filing is Unum Therapeutics Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2019, filed August 12, 2019. The request metadata names Cogent Biosciences, but the filing identifies Unum Therapeutics (Nasdaq: UMRX) as the registrant.
Unum was a clinical-stage cell-therapy company developing ACTR and BOXR platforms for cancer. It had no approved products and no product-sale revenue; reported revenue came from its Seattle Genetics collaboration.
Financial performance and liquidity
| Metric | Q2 2019 | Q2 2018 | Six months 2019 | Six months 2018 |
|---|---|---|---|---|
| Collaboration revenue | $3.1 million | $1.7 million | $6.2 million | $3.9 million |
| Research and development | $10.6 million | $9.1 million | $23.0 million | $17.3 million |
| General and administrative | $3.1 million | $2.0 million | $5.6 million | $3.0 million |
| Total operating expenses | $13.7 million | $11.1 million | $28.6 million | $20.3 million |
| Net loss | $10.5 million | $9.0 million | $22.2 million | $15.8 million |
| Net loss per share | $0.34 | $0.31 | $0.73 | $0.80 |
For the six months, operating cash outflow was $22.9 million, versus $15.9 million a year earlier. Investing activities provided $22.9 million, largely from marketable-security maturities and sales; financing provided $0.1 million. Cash, cash equivalents and restricted cash increased by $0.2 million to $57.1 million, including $55.9 million of cash and cash equivalents and $1.3 million of restricted cash at June 30.
Total assets were $69.3 million and total liabilities were $29.6 million. The balance sheet included $15.2 million of deferred revenue and $6.8 million of operating lease liabilities. No term loans had been drawn; up to $15 million was available under the amended bank facility. The filing does not present a meaningful product gross margin, given the absence of product sales.
Changes versus the prior comparable period
- Q2 collaboration revenue rose $1.5 million, which management attributed primarily to increased program activity. First-half revenue rose $2.3 million.
- First-half operating expenses increased $8.3 million, mainly from higher clinical and manufacturing activity, headcount and public-company costs. First-half net loss widened by $6.4 million.
- Cash and cash equivalents were nearly unchanged from year-end, but marketable securities declined from $22.9 million to zero as securities matured or were sold. The company adopted lease accounting in 2019, recording a right-of-use asset and lease liability.
Outlook, commentary, risks and unusual items
Management expected cash and cash equivalents, excluding available loan borrowings, to fund operations and capital expenditures into early 2021. The filing also cautions that this estimate depends on assumptions and that additional financing may be needed. The company had filed a shelf registration allowing up to $150 million of securities and an at-the-market sales agreement for up to $50 million of common stock; no shares had been sold under the sales agreement by June 30.
A material post-quarter development was the FDA’s July 2019 partial clinical hold on the ACTR087-plus-rituximab ATTCK-20-2 trial, following a safety report concerning a patient who experienced serious adverse events and later died of septic shock. The investigator reported the fatal event as related to ACTR087. Unum said it was working with the FDA and planned to report trial data by year-end. This safety event and regulatory action are significant risks; the filing does not establish their ultimate effect on the program.
Other stated plans included an update on ACTR707 plus rituximab (ATTCK-20-03) in late 2019, data from the ACTR087-plus-SEA-BCMA trial in the second half of 2019, and preliminary safety data for ACTR707 plus trastuzumab at year-end. The company also planned to present BOXR1030 preclinical data in the second half of 2019. These are expectations, not guaranteed outcomes. The company anticipated continued operating losses and identified clinical and regulatory outcomes, manufacturing capacity, vendor dependence, financing needs and competition as principal risks.
Commitments included $2.4 million of non-cancelable contract-manufacturing minimum purchases over the following 12 months and future office-lease payments. No material legal proceedings were reported.
Important facts for investors to verify
- Confirm the registrant identity and ticker: this filing is for Unum Therapeutics (UMRX), not the company named in the request metadata.
- Track FDA communications and the status and consequences of the partial hold on ATTCK-20-2, including any further safety disclosures.
- Assess ACTR707 trial progress and whether the planned late-2019 updates occurred; early Phase 1 findings may not predict later results.
- Monitor cash use, collaboration receipts, actual runway, and any use of the bank facility, shelf registration or at-the-market offering.
- Review clinical-manufacturing commitments and whether the Seattle Genetics collaboration’s remaining performance obligations and expected revenue timing change.